Nov 12, 2024, 13:44
James Gulley: First-in-class bispecific antibody that targets TCR Vbeta chain
James L. Gulley, Director of the Medical Oncology Service at National Cancer Institute, shared a post on X:
”I am delighted to give you the SITC 2024 presentation details of the first-in-human, international study of this first-in-class bispecific antibody that targets TCR Vbeta chain and brings with it IL-2.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19